` CHRO (Chromocell Therapeutics Corp) vs S&P 500 Comparison - Alpha Spread

C
CHRO
vs
S&P 500

Over the past 12 months, CHRO has significantly outperformed S&P 500, delivering a return of +256% compared to the S&P 500's +14% growth.

Stocks Performance
CHRO vs S&P 500

Loading
CHRO
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CHRO vs S&P 500

Loading
CHRO
S&P 500
Difference
www.alphaspread.com

Performance By Year
CHRO vs S&P 500

Loading
CHRO
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Chromocell Therapeutics Corp vs Peers

S&P 500
CHRO
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Chromocell Therapeutics Corp
Glance View

Market Cap
3.8m USD
Industry
Biotechnology

Chromocell Therapeutics Corp is a US-based company operating in Biotechnology industry. The company is headquartered in North Brunswick, New Jersey and currently employs 3 full-time employees. The company went IPO on 2024-02-16. Chromocell Therapeutics Corporation is a clinical-stage biotech company, which is focused on developing and commercializing therapeutics to alleviate pain. The firm's clinical focus is to selectively target the sodium ion-channel, NaV1.7, as well as other receptors in the NaV family. Its lead compound, CC8464, is designed to address both the underlying condition and mitigate the burning pain symptoms, which erythromelalgia (EM) patients experience by blocking the NaV1.7 sodium channel. CC8464 has completed Phase I study. A total of approximately 207 healthy subjects have been dosed in four Phase I studies (CC8464-1001, CC8464-1002, CC8464-1003, and 1807-CL-0102) with study treatment.

CHRO Intrinsic Value
Not Available
C
Back to Top